El-Dawla Reham Ezz, Abdelhaleem Maryam, Abdelhamed Amr
Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Indian J Dermatol Venereol Leprol. 2023 Jan-Mar;89(2):195-203. doi: 10.25259/IJDVL_1011_20.
Chronic telogen effluvium is characterised by diffuse loss of hair of the scalp. One of the emerging lines of treatment is platelet-rich plasma. However, not much of published data exist.
A pilot study was conducted on chronic telogen effluvium patients to evaluate the efficacy and safety of platelet-rich plasma, and to compare two different methods of platelet-rich plasma preparation.
The study included 30 female patients with chronic telogen effluvium. Patients were randomised into three groups: Group (1): Special platelet-rich plasma tubes centrifuged at 3500 rpm; Group (2): Ordinary laboratory tubes centrifuged at 1000 rpm; Group (3): Normal saline as a placebo. Patients' evaluation was done with visual analog scale, hair pull test, trichoscopy, photos, satisfaction questionnaire, and safety. All patients received four monthly sessions. Patients were evaluated one month and three months after the last session.
The hair pull test,visual analogue scale, and patient satisfaction results showed a statistically significant difference between group 1 vs. group 3 and group 2 vs.group 3 at one and three months after the sessions, while there was no difference between group1 vs. group 2. Trichoscopy results (baseline, one and three months after treatment) showed a significant increase in hair density and thickness in the frontal area, temporal area, and the vertex in groups 1 and 2 only. There was no statistically significant difference between the three groups with regards to side effects.
The sample size was small with ten patients in each group. Furthermore, the follow-up of patients was for only three months.
Platelet-rich plasma could be considered as a promising therapy for patients with chronic telogen effluvium with an excellent safety profile. The ordinary laboratory low-cost tubes might be a reliable alternative to the expensive special platelet-rich plasma kits tubes. The trial registry number is PACTR202006539654415.
慢性休止期脱发的特征是头皮弥漫性脱发。新兴的治疗方法之一是富含血小板血浆。然而，已发表的数据不多。
对慢性休止期脱发患者进行一项初步研究，以评估富含血小板血浆的疗效和安全性，并比较两种不同的富含血小板血浆制备方法。
该研究纳入了30名患有慢性休止期脱发的女性患者。患者被随机分为三组：第1组：使用特殊的富含血小板血浆管，以3500转/分钟的速度离心；第2组：使用普通实验室管，以1000转/分钟的速度离心；第3组：使用生理盐水作为安慰剂。通过视觉模拟量表、拔毛试验、毛发镜检查、照片、满意度问卷和安全性对患者进行评估。所有患者每月接受四次治疗。在最后一次治疗后1个月和3个月对患者进行评估。
拔毛试验、视觉模拟量表和患者满意度结果显示，在治疗后1个月和3个月时，第1组与第3组以及第2组与第3组之间存在统计学显著差异，而第1组与第2组之间没有差异。毛发镜检查结果（基线、治疗后1个月和3个月）显示，仅第1组和第2组的额部、颞部和头顶区域的头发密度和厚度有显著增加。三组在副作用方面没有统计学显著差异。
样本量较小，每组有10名患者。此外，对患者的随访仅为3个月。
富含血小板血浆可被视为慢性休止期脱发患者的一种有前景的治疗方法，安全性良好。普通实验室低成本管可能是昂贵的特殊富含血小板血浆试剂盒管的可靠替代品。试验注册号为PACTR202006539654415。
